Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

USPTO Finds Claims Of Two Of Moderna’s mRNA Patents Unpatentable: What’s Next In The Vaccine Wars? Legal News and Analysis - ...

Rep. Marjorie Taylor Greene calls for yanking FDA approval of COVID-19 vaccines, says that "COVID-19 vaccines are causing ...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...

Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales performance of its recently launched RSV vaccine. There have also been several third-party reports ...

Is MRNA stock a sell? It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global ...